Lonafarnib (SCH66336)

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
16023
Phase I study of lonafarnib (SCH66336) in combination with Herceptin plus paclitaxel in HER-2 neu overexpressing breast cancer.
16027
Phase I study of SCH66336(lonafarnib), a farnesyl protein transferase inhibitor in combination with temozolomide in gliomas

Back to Protocol section